Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies

FierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts

Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter

LabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media

Lonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post

Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN

Thermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance

eLifeThe NTR/prodrug revolution: Tools for controlling cell loss and regeneration

Bio-Gene Technology LtdBio-Gene lifts placement size with additional shares and options - TipRanks

10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.com

Eli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits

PfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma

Endpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for Voyxact